Global Epidemiology· 2026Q2
Twelve-month all-cause mortality after initial COVID-19 vaccination with Pfizer-BioNTech or mRNA-1273 among adults living in Florida: Statewide cohort study
- 3citations
- Q2SCImago
- 2026year
Short summary
Adults in Florida receiving the Pfizer-BioNTech (BNT162b2) vaccine had a 41% higher risk of all-cause mortality (784 vs. 562 deaths per 100,000) over 12 months compared to those receiving Moderna (mRNA-1273).
AI-generated from the title and abstract; the full text is not read.
Key points
- Pfizer-BioNTech (BNT162b2) recipients had a 41% higher risk of all-cause mortality (OR 1.407) compared to Moderna (mRNA-1273) recipients.
- Mortality rates were 783.6 per 100,000 for Pfizer vs. 562.4 per 100,000 for Moderna over 12 months.
- Increased mortality risk was observed for all-cause, cardiovascular, COVID-19, and non-COVID-19 causes.
- Robustness analyses suggested results were not significantly altered by unobserved confounding.
AI-generated from the title and abstract; the full text is not read.
Abstract
ABSTRACT Comparative effects of the mRNA COVID-19 vaccines on mortality and other health outcomes are uncertain. Matched cohort analysis of 1,962,822 adults living in Florida who received a first dose of either BNT162b2 (Pfizer) or mRNA-1273 (Moderna) between December 18, 2020, and August 31, 2021, was used to examine 12-month risk of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality. Matching was performed on seven criteria, including census tract. Compared with mRNA-1273 recipients, BNT162b2 recipients had significantly higher risk for all-cause mortality (783.6 vs. 562.4 deaths per 100,000; odds ratio, OR [95% CI]: 1.407 [1.358, 1.457]), cardiovascular mortality, COVID-19 mortality and non-COVID-19 mortality. Negative control outcomes and robustness analyses did not show any indication of meaningful unobserved residual confounding that is likely to alter the results. The results of this study are consistent with cumulative evidence from prior literature showing worse outcomes in recipients of BNT162b2 compared to mRNA-1273. Primary Funding Source The study did not receive any external funding.
The authors' abstract, as published at the source. Global Epidemiology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Infectious Diseases
Infectious DiseasesMedicine